Logo image of IGMS

IGM BIOSCIENCES INC (IGMS) Stock Fundamental Analysis

NASDAQ:IGMS - Nasdaq - US4495851085 - Common Stock - Currency: USD

1.27  -0.03 (-2.31%)

After market: 1.28 +0.01 (+0.79%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IGMS. IGMS was compared to 550 industry peers in the Biotechnology industry. While IGMS has a great health rating, there are worries on its profitability. IGMS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year IGMS has reported negative net income.
IGMS had a negative operating cash flow in the past year.
In the past 5 years IGMS always reported negative net income.
In the past 5 years IGMS always reported negative operating cash flow.
IGMS Yearly Net Income VS EBIT VS OCF VS FCFIGMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

IGMS has a Return On Assets (-49.53%) which is comparable to the rest of the industry.
IGMS's Return On Equity of -52.48% is fine compared to the rest of the industry. IGMS outperforms 63.82% of its industry peers.
With an excellent Return On Invested Capital value of 7.99%, IGMS belongs to the best of the industry, outperforming 93.82% of the companies in the same industry.
Industry RankSector Rank
ROA -49.53%
ROE -52.48%
ROIC 7.99%
ROA(3y)-58.3%
ROA(5y)-50.04%
ROE(3y)-202.16%
ROE(5y)-139.04%
ROIC(3y)N/A
ROIC(5y)N/A
IGMS Yearly ROA, ROE, ROICIGMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

IGMS has a Operating Margin of 7.04%. This is amongst the best in the industry. IGMS outperforms 92.91% of its industry peers.
IGMS does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM 7.04%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IGMS Yearly Profit, Operating, Gross MarginsIGMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so IGMS is destroying value.
IGMS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IGMS has more shares outstanding
IGMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IGMS Yearly Shares OutstandingIGMS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
IGMS Yearly Total Debt VS Total AssetsIGMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -2.35, we must say that IGMS is in the distress zone and has some risk of bankruptcy.
IGMS's Altman-Z score of -2.35 is in line compared to the rest of the industry. IGMS outperforms 50.36% of its industry peers.
There is no outstanding debt for IGMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.35
ROIC/WACC0.81
WACC9.81%
IGMS Yearly LT Debt VS Equity VS FCFIGMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

IGMS has a Current Ratio of 17.66. This indicates that IGMS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IGMS (17.66) is better than 92.00% of its industry peers.
IGMS has a Quick Ratio of 17.66. This indicates that IGMS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 17.66, IGMS belongs to the best of the industry, outperforming 92.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.66
Quick Ratio 17.66
IGMS Yearly Current Assets VS Current LiabilitesIGMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.01% over the past year.
Looking at the last year, IGMS shows a very strong growth in Revenue. The Revenue has grown by 4881.11%.
EPS 1Y (TTM)85.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
Revenue 1Y (TTM)4881.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11353.19%

3.2 Future

Based on estimates for the next years, IGMS will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.78% on average per year.
IGMS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.79% yearly.
EPS Next Y59.87%
EPS Next 2Y27.79%
EPS Next 3Y19.3%
EPS Next 5Y11.78%
Revenue Next Year249.45%
Revenue Next 2Y126.25%
Revenue Next 3Y73.98%
Revenue Next 5Y2.79%

3.3 Evolution

IGMS Yearly Revenue VS EstimatesIGMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5M 10M
IGMS Yearly EPS VS EstimatesIGMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IGMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IGMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IGMS Price Earnings VS Forward Price EarningsIGMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -5.77
IGMS Per share dataIGMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

IGMS's earnings are expected to grow with 19.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.79%
EPS Next 3Y19.3%

More info and screens

0

5. Dividend

5.1 Amount

IGMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IGM BIOSCIENCES INC

NASDAQ:IGMS (8/13/2025, 8:15:46 PM)

After market: 1.28 +0.01 (+0.79%)

1.27

-0.03 (-2.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/amc
Earnings (Next)11-06 2025-11-06/amc
Inst Owners53.06%
Inst Owner Change-4.01%
Ins Owners2.48%
Ins Owner Change-0.37%
Market Cap76.44M
Analysts48.89
Price Target1.27 (0%)
Short Float %1.86%
Short Ratio0.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)297.19%
Min EPS beat(2)-21.95%
Max EPS beat(2)616.34%
EPS beat(4)2
Avg EPS beat(4)147.4%
Min EPS beat(4)-23.77%
Max EPS beat(4)616.34%
EPS beat(8)5
Avg EPS beat(8)-167.29%
EPS beat(12)9
Avg EPS beat(12)-109.67%
EPS beat(16)12
Avg EPS beat(16)-83.61%
Revenue beat(2)1
Avg Revenue beat(2)2105.97%
Min Revenue beat(2)-84.23%
Max Revenue beat(2)4296.17%
Revenue beat(4)3
Avg Revenue beat(4)1075.96%
Min Revenue beat(4)-84.23%
Max Revenue beat(4)4296.17%
Revenue beat(8)3
Avg Revenue beat(8)515.32%
Revenue beat(12)5
Avg Revenue beat(12)338.08%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-25.93%
PT rev (3m)-33.33%
EPS NQ rev (1m)37.73%
EPS NQ rev (3m)-16%
EPS NY rev (1m)0%
EPS NY rev (3m)-21.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)58.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.53
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA -5.77
EPS(TTM)-0.55
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)-2.63
FCFYN/A
OCF(TTM)-2.59
OCFYN/A
SpS2.41
BVpS1.68
TBVpS1.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -49.53%
ROE -52.48%
ROCE 10.11%
ROIC 7.99%
ROICexc N/A
ROICexgc N/A
OM 7.04%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.3%
ROA(5y)-50.04%
ROE(3y)-202.16%
ROE(5y)-139.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 29.58%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.66
Quick Ratio 17.66
Altman-Z -2.35
F-Score5
WACC9.81%
ROIC/WACC0.81
Cap/Depr(3y)125.69%
Cap/Depr(5y)474.33%
Cap/Sales(3y)578.65%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
EPS Next Y59.87%
EPS Next 2Y27.79%
EPS Next 3Y19.3%
EPS Next 5Y11.78%
Revenue 1Y (TTM)4881.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11353.19%
Revenue Next Year249.45%
Revenue Next 2Y126.25%
Revenue Next 3Y73.98%
Revenue Next 5Y2.79%
EBIT growth 1Y104.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.17%
EBIT Next 3Y22.7%
EBIT Next 5YN/A
FCF growth 1Y19.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.46%
OCF growth 3YN/A
OCF growth 5YN/A